Takeda shares came under valuation scrutiny after recent gains and mixed pipeline news, including a DNL593 collaboration exit and positive Phase 3 data for zasocitinib. The analyses said the stock was trading close to or above widely followed fair value estimates, while DCF assumptions pointed to much higher implied value.
Northwestern Medicine scientists discovered that N-acetyl-L-leucine (NALL), an FDA-approved compound, promotes neuroprotective effects in experimental Parkinson's disease models by targeting multiple molecular pathways simultaneously.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07638813 |
MSC-Exosome Therapy for Frontotemporal Dementia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT06377033 |
Using the EHR to Advance Genomic Medicine Across a Diverse Health System |
RECRUITING | NA |
| NCT06209515 |
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study |
ACTIVE_NOT_RECRUITING | |
| NCT06064890 |
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) |
RECRUITING | PHASE1/PHASE2 |
| NCT05742698 |
Nabilone for Agitation in Frontotemporal Dementia |
TERMINATED | PHASE2 |
| NCT04875416 |
Phenotype, Genotype and Biomarkers 2 |
ACTIVE_NOT_RECRUITING | |
| NCT04516499 |
Neurofilament Surveillance Project (NSP) |
ACTIVE_NOT_RECRUITING | |
| NCT04408625 |
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04220021 |
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03912987 |
TRIAL READY (Clinical Trial Readiness) |
ACTIVE_NOT_RECRUITING |
